PTPN11 mutations are associated with mild growth hormone resistance in individuals with noonan syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 9, 2005, Pages 5377-5381

  Binder, G ^a   Neuer, K ^a   Ranke, M B ^a   Wittekindt, N E ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE RECEPTOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; RECOMBINANT GROWTH FACTOR;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; EXON; FACE DYSMORPHIA; FEMALE; GENE; GENE SEQUENCE; GENETIC CODE; GROWTH HORMONE RELEASE; HEART SEPTUM DEFECT; HUMAN; MALE; MISSENSE MUTATION; NOONAN SYNDROME; POLYMERASE CHAIN REACTION; PREPUBERTY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PTPN11 GENE; PULMONARY ARTERY STENOSIS; RADIOIMMUNOASSAY; SHORT STATURE;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MUTATION, MISSENSE; NOONAN SYNDROME; PHENOTYPE; PROTEIN-TYROSINE-PHOSPHATASE;

EID: 24344436765     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2005-0995     Document Type: Article

References (30)

1. Noonan JA 1968 Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease. Am J Dis Child 116:373-380
2. Duncan WJ, Fowler RS, Farkas LG, Ross RB, Wright AW, Bloom KR, Huot DJ, Sondheimer HM, Rowe RD 1981 A comprehensive scoring system for evaluating Noonan syndrome. Am J Med Genet 10:37-50
3. Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, Tietze HU, Doerr HG, Hofbeck M, Singer H, Reis A, Rauch A 2004 Genotype-phenotype correlations in Noonan syndrome. J Pediatr 144:368-374
4. Ranke MB, Heidemann P, Knupfer C, Enders H, Schmaltz AA, Bierich JR 1988 Noonan syndrome: growth and clinical manifestations in 144 cases. Eur J Pediatr 148:220-227
5. Ahmed ML, Foot AB, Edge JA, Lamkin VA, Savage MO, Dunger DB 1991 Noonan's syndrome: abnormalities of the growth hormone/IGF-I axis and the response to treatment with human biosynthetic growth hormone. Acta Paediatr Scand 80:446-450
6. Noordam C, van der Burgt I, Sweep CG, Delemarre-van de Waal HA, Sengers RC, Otten BJ 2001 Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment. Clin Endocrinol (Oxf) 54:53-59
7. Van der Burgt I, Berends E, Lommen E, van Beersum S, Hamel B, Mariman E 1994 Clinical and molecular studies in a large Dutch family with Noonan syndrome. Am J Med Genet 53:187-191
8. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD 2001 Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29:465-468
9. Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, Kucherlapati RS, Jeffery S, Patton MA, Gelb BD 2002 PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 70:1555-1563
10. Musante L, Kehl HG, Majewski F, Meinecke P, Schweiger S, Gillessen-Kaesbach G, Wieczorek D, Hinkel GK, Tinschert S, Hoeltzenbein M, Ropers HH, Kalscheuer VM 2003 Spectrum of mutations in PTPN11 and genotypephenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet 11:201-206
11. Yoshida R, Hasegawa T, Hasegawa Y, Nagai T, Kinoshita E, Tanaka Y, Kanegane H, Ohyama K, Onishi T, Hanew K, Okuyama T, Horikawa R, Tanaka T, Ogata T 2004 Protein-tyrosine phosphatase, nonreceptor type 11 mutation analysis and clinical assessment in 45 patients with Noonan syndrome. J Clin Endocrinol Metab 89:3359-3364
12. Jongmans M, Sistermans EA, Rikken A, Nillesen WM, Tamminga R, Patton M, Maier EM, Tartaglia M, Noordam K, van der Burgt I 2005 Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. Am J Med Genet A 134:165-170
13. Feng GS 1999 SHP-2 tyrosine phosphatase: signaling one cell or many. Exp Cell Res 253:47-54
14. Hof P, Pluskey S, Dhe-Paganon S, Eck MJ, Shoelson SE 1998 Crystal structure of the tyrosine phosphatase SHP-2. Cell 92:441-450
15. Stofega MR, Herrington J, Billestrup N, Carter-Su C 2000 Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol Endocrinol 14:1338-1350
16. Prader A, Largo RH, Molinari L, Issler C 1989 Physical growth of Swiss children from birth to 20 years of age. First Zurich Longitudinal Study of Growth and Development. Helv Paediatr Acta 52(Suppl):1-125
17. Niklasson A, Ericson A, Fryer JG, Karlberg J, Lawrence C, Karlberg P 1991 An update of the Swedish reference standards for weight, length and head circumference at birth for given gestational age (1977-1981). Acta Paediatr Scand 80:756-762
18. Hauffa BP, Lehmann N, Bettendorf M, Mehls O, Dorr HG, Partsch CJ, Schwarz HP, Stahnke N, Steinkamp H, Said E, Sander S, Ranke MB, KIGS/ IGLU Study Group 2004 Central reassessment of GH concentrations measured at local treatment centers in children with impaired growth: consequences for patient management. Eur J Endocrinol 150:291-297
19. Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB 1993 Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 76:1610-1616
20. Blum WF and Schweizer R 2003 Insulin-like growth factors and their binding proteins. In: Ranke MB, ed. Diagnostics of endocrine function in children and adolescents. Basel, Switzerland: Karger; 166-199
21. Tanaka K, Sato A, Naito T, Kuramochi K, Itabashi H, Takemura Y 1992 Noonan syndrome presenting growth hormone neurosecretory dysfunction. Intern Med 31:908-911
22. Spadoni GL, Bernardini S, Cianfarani S, Vaccaro F, Pasquino AM, Cives C, Pucarelli I, Passeri F, Dini F, Boscherini B 1990 Spontaneous growth hormone secretion in Noonan's syndrome. Acta Paediatrica Scand 367(Suppl):157
23. Noordam K, van der Burgt I, Brunner HG, Otten BJ 2002 The relationship between clinical severity of Noonan's syndrome and growth, growth hormone (GH) secretion and response to GH treatment. J Pediatr Endocrinol Metab 15:175-180
24. Rosenfeld RG, HwaV2004 New molecular mechanisms of GH resistance. Eur J Endocrinol 151(Suppl 1):S11-S15
25. Woelfle J, Chia DJ, Massart-Schlesinger MB, Moyano P, Rotwein P 2005 Molecular physiology, pathology, and regulation of the growth hormone/insulin-like growth factor-I system. Pediatr Nephrol 20:295-302
26. Argetsinger LS, Carter-Su C 1996 Mechanism of signaling by growth hormone receptor. Physiol Rev 76:1089-1107
27. Kim SO, Jiang J, Yi W, Feng GS, Frank SJ 1998 Involvement of the Src homology 2-containing tyrosine phosphatase SHP-2 in growth hormone signaling. J Biol Chem 273:2344-2354
28. Yu C-L, Yong-Jiu J, Burakoff SJ 2000 Cytosolic tyrosine dephosphorylation of STAT5. J Biol Chem 275:599-604
29. Chen Y, Wen R, Yang S, Schuman J, Zhang EE, Yi T, Feng G-S, Wang D 2003 Identification of shp-2 as a Stat5a phosphatase. J Biol Chem 278:16520-16527
30. Santos CD, Essioux L, Teinturier C, Tauber M, Goffin V 2004 A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 36:720-724